Skip to main content
. Author manuscript; available in PMC: 2024 Oct 7.
Published in final edited form as: J Physiol. 2022 Oct 14;600(22):4917–4938. doi: 10.1113/JP283513

Figure 6. The activation of adenylyl cyclase disrupts MOR-mediated LTD.

Figure 6.

A, representative eEPSC traces showing the effects of 20 μM forskolin before, during and after DAMGO (0.3 μM, 5 min) application. B–D, AC activation disrupted glutamatergic MOR-LTD (105 ± 5%, unpaired t test, P < 0.0001, t17 = 5.54), showing no changes in eEPSC amplitude after DAMGO bath application (0–10 min baseline vs. final 10 min of recording; paired t test, P = 0.324, t8 = 1.05, n = 9 neurons from four mice). E, representative oEPSC traces showing the effects of 20 μM forskolin before, during and after DAMGO (0.3 μM, 5 min) application in brain slices from Emx1-Ai32 mice. F–H, AC activation disrupted corticostriatal MOR-LTD (105 ± 2%, unpaired t test, P < 0.0001, t13 = 6.65), with no effects in oEPSC amplitude after DAMGO bath application (0–10 min baseline vs. final 10 min of recording; paired t test, P = 0.0576, t5 = 2.455, n = 6 neurons from four mice). I, representative AIC-DLS oEPSC traces showing the effects of 20 μM forskolin before, during and after DAMGO (0.3 μM, 5 min) application. J–L, AC activation blocked specifically AIC MOR-LTD (98 ± 5%, unpaired t test, P = 0.0116, t14 = 2.9), without changes in oEPSC amplitude after DAMGO bath application (0–10 min base-line vs. final 10 min of recording; paired t test, P = 0.702, t8 = 0.396, n = 9 neurons from three mice). Time course data represent means ± SEM. Box plots show average of the final 10 min of recording and represent median and interquartile ranges. ns = not significant, *P < 0.05, ****P < 0.0001.